Bridge Biotherapeutics, Inc.

A Paradoxical Stock Move Of all the stock price reactions in the fourth-quarter 2024 earnings season, the last – that of Bayer – was the most perplexing. Bayer’s stock price opened up in Frankfurt by

South Korean biopharma firms remained active participants in the recent J.P. Morgan Healthcare Conference in San Francisco, which came as the second Trump Administration assumed power in the US and a

The busy week for the idiopathic pulmonary fibrosis (IPF) space has continued apace with the news that Roche is selling off rights to one of the two drugs currently approved for the debilitating and f

Signs of broader recovery are emerging in the South Korean biotech sector following the landmark US approval of Yuhan Corporation 's novel lung cancer drug Lazcluze (lazertinib) in August through lic